Author: @admin

Post

Nabriva Therapeutics Announces Closing of up to a $75 million Term Loan

-Financing Strengthens Cash Position Ahead of Two Potential Product Launches in 2019- DUBLIN, Ireland , Dec. 21, 2018 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to READ FULL TEXT

December 21, 2018December 21, 2018by In News
Post

Nabriva Therapeutics Submits New Drug Applications to U.S. Food and Drug Administration for Intravenous and Oral Lefamulin to Treat Community-Acquired Bacterial Pneumonia in Adults

DUBLIN, Ireland , Dec. 20, 2018 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of innovative anti-infective agents to treat serious infections, announced the submission of two New Drug Applications READ FULL TEXT

December 20, 2018December 20, 2018by In News
Post

John H. Johnson Agrees to Become Permanent Chief Executive Officer of Melinta Therapeutics

NEW HAVEN, Conn., Dec. 19, 2018 (GLOBE NEWSWIRE) — Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that John H. Johnson has agreed to become the permanent chief executive officer (CEO) of Melinta, subject to the terms of an employment contract and the...

December 19, 2018December 19, 2018by In News
Post

Melinta Therapeutics Announces Commitment for New Credit Facility of Up to $135 Million

~ Credit Facility has Option to be Converted into Preferred Shares ~ ~ Adjourns Special Meeting of Stockholders Scheduled for December 20, 2018 ~ ~ Reaffirms Product Sales and Cost Savings Guidance ~ NEW HAVEN, Conn., Dec. 19, 2018 (GLOBE NEWSWIRE) — Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company developing and commercializing novel antibiotics...

December 19, 2018December 19, 2018by In News
Post

Proposed Subscription to Raise $25m and Notice of General Meeting

THIS ANNOUNCEMENT (INCLUDING THE APPENDICES) AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, OR INTO ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN...

December 17, 2018December 17, 2018by In News
Post

Proposed Subscription to Raise $25m and Notice of General Meeting

THIS ANNOUNCEMENT (INCLUDING THE APPENDICES) AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, OR INTO ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN...

December 17, 2018December 17, 2018by In News